טוען...
EXTH-82. HIGH NOTCH1 EXPRESSION AND WILD-TYPE P53 DEFINE SYNERGISTIC ACTIVITY BY GAMMA SECRETASE INHIBITORS AND DOXORUBICIN IN GLIOBLASTOMAS
Glioblastoma (GBM) remains one of the most lethal and difficult-to-treat cancers. The poor prognosis of GBM patients is due in part to its resistance to available treatments, which calls for development of novel therapeutic agents/regimen. In this study, we tested a series of patient-derived primary...
שמור ב:
| הוצא לאור ב: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692204/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.372 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|